Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase IIIb Riociguat Study in Inoperable or Residual CTEPH
2012-002104-40Phase 3Completed
- Sponsor
- Bayer
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of riociguat in chronic thromboembolic pulmonary hypertension (CTEPH), pulmonary hypertension (PH), sponsored by Bayer. Started Dec 2012; status: completed.
02
Drugs
riociguat
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)pulmonary hypertension (PH)
Beyond the preview
Go deeper on 2012-002104-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002104-40.